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 Fms-like tyrosine kinase 3 internal tandem duplication (FLT3-ITD) is frequently detected in acute myeloid leukemia
(AML) patients and is associated with a dismal long-term prognosis. FLT3 tyrosine kinase inhibitors provide short-
term disease control, but relapse invariably occurs within months. Pim protein kinases are oncogenic FLT3-ITD tar-
gets expressed in AML cells. We show that increased Pim kinase expression is found in relapse samples from AML
patients treated with FLT3 inhibitors. Ectopic Pim-2 expression induces resistance to FLT3 inhibition in both FLT3-
ITD–induced myeloproliferative neoplasm and AML models in mice. Strikingly, we found that Pim kinases govern
FLT3-ITD signaling and that their pharmacological or genetic inhibition restores cell sensitivity to FLT3 inhibitors.
Finally, dual inhibition of FLT3 and Pim kinases eradicates FLT3-ITD+ cells including primary AML cells. Concomitant
Pim and FLT3 inhibition represents a promising new avenue for AML therapy.van
 o
n
 Septem
ber 8, 2016
ces.sciencem
ag.org/INTRODUCTION
Acute myeloid leukemia (AML) is an aggressive disease caused by the
transformation of hematopoietic progenitor cells due to the acquisition
of genetic alterations (1). Although heterogeneous, many of these le-
sions lead to constitutive activation of protein tyrosine kinases (PTKs)
and growth factor signaling pathways, resulting in the proliferation
and clonal expansion of hematopoietic progenitors (2), with signifi-
cant prognostic implications (3).
Fms-like tyrosine kinase 3 (FLT3) is a member of the class III receptor
tyrosine kinase family, which also includes the FMS, KIT, and platelet-
derived growth factor (PDGF) receptors (4). The FLT3 internal tandem
duplication (FLT3-ITD) mutation is found in blast cells of 20 to 30% of
AML patients and confers a poor prognosis (1). These mutations occur in
the juxtamembrane domain of FLT3 and lead to receptor dimerization
and ligand-independent constitutive activation of downstream signal
transduction pathways, including mitogen-activated protein kinase
(MAPK)/extracellular signal–regulated kinase (ERK) and signal
transducer and activator of transcription 5 (STAT5) (5).Although the question of whether FLT3-ITD is a cooperating or
initiating mutation in AML remains the subject of debate (6, 7), FLT3-
ITD may drive leukemogenesis from early hematopoietic progenitors
(8). The high relapse rate observed after chemotherapy prompted the
development of FLT3 inhibitors (FLT3i), which demonstrated clinical
efficacy in FLT3-ITD–positive (FLT3-ITD+) AML but failed to induce
long-lasting remissions (9). Twenty percent of patients relapsing on FLT3i
therapy have detectable FLT3-ITD tyrosine kinase domain mutations
(TKD)—mostly at the D835 position—representing the most commonly
described resistance mechanism to FLT3i (6, 9). Elucidation of the
molecular pathways involved in FLT3i resistance is therefore critical
for the development of targeted therapies capable of inducing durable
responses in affected patients.
Pim serine/threonine kinases are frequently overexpressed in human
cancers (10). Named for their role as the provirus integration site for the
Moloney murine leukemia virus, Pim kinases, including Pim-1, Pim-2,
and Pim-3, have both overlapping and nonoverlapping functions and
contribute to cell transformation in cooperation with oncogenes such
as myc or deregulated PTKs, including TEL/JAK2, BCR/ABL, and FLT3-
ITD (11–15). We previously reported increased Pim-2 protein expression
in AML cells compared to normal CD34+ hematopoietic progenitors (16).
Here, we aimed to explore the role of Pim kinases in FLT3i-resistant
AML. We found that Pim kinase expression is increased in primary
samples from AML patients relapsing on FLT3i therapy with sorafenib.
Ectopic Pim kinase expression impairs the response to FLT3i in vitro
and in models of FLT3-ITD–induced myeloproliferative neoplasm (MPN)
and AML, using a PIM2 allele, in mice. Pim kinase inhibition enhanced
FLT3i activity across multiple FLT3-mutant cell lines and in FLT3-ITD+
primary AML samples. Mechanistically, Pim kinases exert proximal con-
trol of FLT3-ITD signaling, and their inhibition facilitates the activity of
FLT3i against FLT3-ITD receptors. Combined inhibition of Pim and
FLT3 therefore warrants further evaluation in clinical trials in AML.1 of 13
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 RESULTS
Increased Pim kinase expression is found in
sorafenib-resistant primary AML samples and confers
resistance to FLT3 inhibition in vivo
Pim protein kinases are well-documented FLT3-ITD targets and there-
fore may have a potential role in FLT3-ITD–mediated cell transfor-
mation (14, 17). We investigated the role of these oncogenic kinases
in FLT3i resistance, which inevitably occurs after a short interval in
FLT3-ITD+ AML patients (9, 18).
We compared Pim kinase protein expression in paired primary
samples from FLT3-ITD+ AML patients at the time of diagnosis (FLT3i-
naïve) and after relapse on treatment with sorafenib (FLT3i-resistant)
(Table 1). Whereas Pim kinase expression decreased in three of seven
sorafenib-treated samples—which was expected considering the docu-
mented regulation of Pim kinases by FLT3-ITD (14, 17)—Pim-2 ex-
pression unexpectedly increased in four of seven FLT3i-resistant
compared to FLT3i-naïve paired samples (Fig. 1A). Pim-1 protein expres-
sion, which was low to absent in FLT3i-naïve samples, was increased
in two FLT3i-resistant samples, decreased in one sample, and not de-
tected in three samples (Fig. 1A). We found an FLT3-ITD kinase do-
main mutation by sequencing in four of seven sorafenib-resistant
samples, which was not detected in sorafenib-naïve samples but with-
out any correlation with the expression of Pim kinases (Fig. 1A, right,
and Table 1). Thus, increased Pim kinase expression may occur in
FLT3i-resistant primary AML cells.
We further used Pim-2 as a representative model of the Pim kinase
family because Pim-2 is more frequently detected than Pim-1 in pri-
mary AML samples and AML cell lines (fig. S1A). We used a well-
characterized experimental model of FLT3-ITD–induced MPN (19),
in which mice received FLT3-ITD+ transformed hematopoietic pro-
genitor cells or cells expressing both FLT3-ITD and human PIM2
(FLT3-ITD/PIM2). Compared to their syngeneic counterparts, recipi-Green et al. Sci. Adv. 2015;1:e1500221 18 September 2015ents of FLT3-ITD+ cells had decreased body weight (Fig. 1B), increased
spleen weight and cellularity (Fig. 1, C and D), increased white blood
cell (WBC) and monocyte counts, and decreased platelet counts (Fig.
1E). These parameters did not differ between mice receiving FLT3-
ITD– or FLT3-ITD/PIM2–transduced cells (Fig. 1, B to E), suggesting
that ectopic Pim-2 expression did not modify tumor burden. Engraft-
ment of these cells was confirmed by immunohistochemistry of mouse
spleen (Fig. 1F).
Treatment with the FLT3i AC220 commenced at disease onset, as
defined by a WBC count of more than 104/ml. AC220 therapy resulted
in a reduction in WBC and monocyte counts, diminished myeloid cells
expansion (Fig. 1, G and H), and decreased spleen weight (Fig. 1I) in
mice injected with FLT3-ITD but not FLT3-ITD/PIM2 cells. Moreover,
cellular proliferation in the splenic red pulp as measured by Ki-67+
staining was reduced with AC220 treatment in FLT3-ITD but not in
FLT3-ITD/PIM2 recipients (Fig. 1J). Pim-2 expression in FLT3-ITD+
hematopoietic cells is thus sufficient to induce FLT3i resistance
in vivo.
Pim kinases are FLT3-ITD targets involved in resistance to
FLT3 inhibition in AML
We used a doxycycline (Dox)–inducible short hairpin RNA (shRNA)
to achieve targeted FLT3 knockdown in AML cell lines. FLT3 protein
expression was efficiently suppressed in all cell lines tested (HL-60,
OCI-AML3, MV4-11, and MOLM-14) but correlated with reduced
Pim-1 and Pim-2 expression only in FLT3-ITD+ cell lines (MV4-11 and
MOLM-14, Fig. 2A). In MOLM-14 and MV4-11 cells, FLT3 knock-
down increased annexin V binding, in contrast to the results observed
in two FLT3 wild-type AML cell lines, OCI-AML3 and HL-60 (fig. S2A),
suggesting an addiction to FLT3-ITD signaling in these cell lines.
In the FLT3-ITD+ MOLM-14 AML cell line, Pim-2 expression was
constitutive and controlled by multiple signaling relays downstream of
FLT3-ITD, in contrast to the observations made in the FLT3 wild-type o
n
 Septem
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g/Table 1. Clinicopathologic characteristics of seven patients with FLT3-ITD+ AML treated on sorafenib monotherapy trial. G, gender; A, age (in
years); FAB, French-American-British classification; WCC, white cell count (109/liter); Blast, percentage of bone marrow blast cells; NPM1, nucleophosmin
1 mutation status; Karyo., karyotype; FLT3-TKD, FLT3 tyrosine kinase domain mutation status; Naïve, pre-sorafenib sample; Res., sample collected after
disease evolution upon sorafenib treatment; NS, not specified; NA, not available; WT, wild type; Mut, mutated; 7 + 3, daunorubicin and cytarabine; HDAC,
high-dose cytarabine; MTZ/VP16/AC, mitoxantrone, etoposide, and cytarabine; MACE-DEX, mitoxantrone, cytarabine, etoposide, and dexamethasone; ICE,
idarubicin, cytarabine, etoposide; CLARA, clofarabine, cytarabine; MTZ/MDAC, mitoxantrone, medium-dose cytarabine; 5AZA, 5-azacytidine; Y and N, pres-
ence or absence of TKD mutations in sorafenib-naïve and sorafenib-resistant samples.016Patient G/A FAB WCC Blast NPM1 Karyo. Previous treatments
FLT3-TKD*Naïve Res.AML#1 M/54 NS 167 81 NA Complex† 7 + 3, HDAC×2, MACE-DEX N NAML#2 M/34 M6 2 6 (75)‡ WT 46, XY 7 + 3, ICE, CLARA, MTZ/MDAC, 5AZA N YAML#3 F/57 M1 19 54 WT 46, XX 7 + 3, MTZ/MDAC×3 N NAML#4§ F/47 NS 25 78 Mut. 46, XX 7 + 3, ICE×2 N YAML#5 F/87 M1 260 94 NA 46, XX Not eligible N YAML#6 F/43 NS 18 55 WT Complex¶ 7 + 3, HDAC×2, MTZ/VP16/AC N NAML#7 F/67 M1 102 95 NA 46, XX 7 + 3, HDAC×2, 5AZA N Y*D835 mutation of FLT3-TKD was examined as described (18) on peripheral blood cells. †42~48,XY,del(5)(p13),+del(6)(q16),del(12)(p11.2),-14,-15,-17,t(17;19)(q21;p13),-20,+1~6mar[cp8]/46,XY[7].
‡The percentage of blast cells of bone marrow was 75% among the nucleated cells. §The clinical information and the FLT3-TKD status of patient AML#7 have been reported (18). ¶46,XX,i(17)
(q10)[6]/46,XX,del(5)(q34)[3]/46,XX,add(11)(p11.2)[2]/46,XX,del(11)(15.2)[2]/46,XX[20].2 of 13
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Fig. 1. Increased Pim kinase expression is found in sorafenib-resistant primary AML samples and confers resistance to FLT3 inhibition in vivo. (A)
Left: Western blotting with Pim-1 and Pim-2 antibodies was performed on seven paired primary AML samples from patients before TKI treatment [naïve (N)]
and after relapse (R) following sorafenib therapy. Right: FLT3-TKD sequencing (−, absence of mutation; +, detection of a D835 mutation) in naïve or resistant/
relapsed (Res) AML samples. (B to F) Six- to 8-week-old B6 mice were transplanted with bone marrow (BM)–derived hematopoietic precursors transduced
with FLT3-ITD (black), FLT3-ITD and human Pim-2 (FLT3-ITD/PIM2; gray), or control (white) constructs. Eight weeks after adoptive transfer, body weight (B),
spleen weight (C), spleen cell counts (D), and peripheral blood counts (total leukocytes, monocytes, and platelets) (E) were determined, and immuno-
histochemical analysis of FLT3 and Pim-2 protein expression was performed on spleen sections (F) (n = 4 for each). (G and H) Peripheral blood counts (total
leukocytes, monocytes, and platelets) from mice adoptively transferred with bone marrow precursors expressing FLT3-ITD (black bars) or FLT3-ITD/PIM2 (gray
bars), treated or not with AC220 for 1 week (n = 4 for each). (I) Spleen weight relative to body weight in mice transduced with FLT3-ITD (white bars) or
FLT3-ITD/PIM2 (black bars) and treated with vehicle or AC220. (J) Hemalun-Erythrosine-Safran (HES) and Ki-67 staining of spleen sections from (G) and (H). Results
in the graphs are expressed as means ± SEM. *P < 0.05; **P < 0.01; ns, not significant. b-Actin was used as a loading control for all Western blots.Green et al. Sci. Adv. 2015;1:e1500221 18 September 2015 3 of 13
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Fig. 2. Pim kinases are FLT3-ITD targets involved in resistance to FLT3 inhibition in AML. (A) AML cell lines (HL-60, OCI-AML3, MV4-11, and MOLM-14)
were transduced via lentivirus with Dox-inducible anti-FLT3 shRNA vectors. shRNA induction was achieved with Dox (200 ng/ml). Western blots were
performed using FLT3, Pim-1, and Pim-2 antibodies. WT, wild type. (B) MOLM-14 and OCI-AML3 cells were cultured with FLT3-L and/or 5 nM AC220.
Tyrosine phosphorylation was evaluated in FLT3 immunoprecipitates. Pim-1, Pim-2, phospho-STAT5 (Y694), and STAT5 levels were detected in whole-cell
lysates by immunoblotting. (C) MOLM-14 cells were treated for 24 hours with 5 nM AC220 (left), and MOLM-14 and MV4-11 cells were transduced with
inducible shFLT3 and treated with Dox (200 ng/ml) for 48 hours (right). Pim-1 and Pim-2 mRNA levels were quantified by real-time polymerase chain
reaction. Gene expression was normalized to the HPRT (hypoxanthine-guanine phosphoribosyltransferase) levels (n = 3). (D) STAT5A/B gain (right) or loss
(left) of function in MOLM-14 cells transduced with lentivirus. STAT5A, STAT5B, Pim-1, Pim-2, and Bcl-xL protein levels were evaluated by immunoblotting.
(E) MOLM-14 cells were separately transduced with a PIM1- or PIM2-expressing vector or an empty vector. Ectopic expression of Pim-1 and Pim-2 was
verified by immunoblotting (right). Cells were treated with vehicle or 1 nM AC220 for 48 hours, and cell viability was assessed by an UptiBlue assay (left)
(n = 3). (F) MOLM-14 cells expressing an FLT3 shRNA in a Dox-inducible manner were transduced with a Pim2 (murine Pim-2) allele or a control vector.
After 48 hours of culture in the presence of Dox (200 ng/ml), FLT3 and murine Pim-2 expression was assessed by immunoblotting, and apoptosis was
measured by annexin V staining. (G and H) MOLM-14 cells were transduced via lentivirus with a control vector (Dox-inducible anti–Pim-2 shRNA vector) or
with Pim2 lentivirus and xenografted into nude mice. (E) Tumor growth was assessed in mice treated with AC220 (1 mg/kg) (initiated once the tumor size
reached 100 mm3) with (black circle) or without (white circle) Pim2 transduction. Growth of untreated xenotransplanted MOLM-14 cells is also provided
(white square box). The means of the individual tumor sizes are plotted (n = 8). (F) Kaplan-Meier survival curve analysis of MOLM-14 cells transduced
(dashed line) or not (solid line) with Pim2, transplanted into nude mice, and treated with AC220 (n = 8). Results are expressed as means ± SEM. b-Actin was
used as a loading control for all Western blots. *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001.Green et al. Sci. Adv. 2015;1:e1500221 18 September 2015 4 of 13
R E S EARCH ART I C L E
 o
n
 Septem
ber 8, 2016
http://advances.sciencem
ag.org/
D
ow
nloaded from
 OCI-AML3 cell line (fig. S2, A and B). Pim-1 and Pim-2 protein
expression also decreased with AC220 therapy in MOLM-14 cells (Fig.
2B). In OCI-AML3 cells, stimulation with FLT3 ligand (FLT3-L)
enhanced FLT3 tyrosine phosphorylation but had no impact on Pim
kinase expression (Fig. 2B). Collectively, these data suggest that Pim
kinases are specific FLT3-ITD targets without implication of the wild-
type FLT3 allele in their regulation.
Previous work suggests that STAT5 activation by endoplasmic
reticulum–anchored FLT3-ITD may transactivate Pim kinases along
with other targets such as Bcl-xL (20, 21). We quantified Pim-1 and
Pim-2 mRNA upon FLT3 pharmacological or genetic inhibition. In
MOLM-14 and MV4-11 FLT3-ITD+ cells, FLT3 inhibition correlated
to decreased Pim-1 transcript levels, whereas Pim-2 mRNA remained
at baseline levels (Fig. 2C). Moreover, STAT5 knockdown in MOLM-
14 cells induced Pim-1, but not Pim-2, depletion (Fig. 2D). In contrast,
ectopic expression of STAT5A or STAT5B induced Pim-1 expression
without Pim-2 modification (Fig. 2D). Pim-1 and Pim-2 are thus dif-
ferentially regulated downstream of FLT3-ITD without implication of
STAT5 in the case of Pim-2 in AML.
We expressed a PIM1 or a PIM2 allele separately in MOLM-14
cells (Fig. 2E). Upon treatment with AC220, cell viability was signif-
icantly preserved in MOLM-14 cells overexpressing Pim-1 or Pim-2
compared to MOLM-14 cells transduced with an empty vector (Fig. 2E).
Pim2 ectopic expression also protected MOLM-14 cells from apoptosis
induced by genetic (Fig. 2F) or chemical (fig. S2D) FLT3 inhibition. Ec-
topic expression of AKT promoted annexin V staining similar to Pim2
expression but did not protect MOLM-14 cells from AC220-induced
cytotoxicity (fig. S2E). Pim kinase expression thus specifically prevented
cytotoxicity upon FLT3 inhibition in AML.
We xenografted nude mice with MOLM-14 cells transduced with a
control or Pim2 allele. AC220 administration was initiated upon disease
detection (Fig. 2G). FLT3i reduced tumor growth and delayed disease
propagation in control animals, showing that MOLM-14 cells are sen-
sitive to FLT3i in vivo, as previously reported (Fig. 2G) (22). In contrast,
mice bearing xenografts ectopically expressing a Pim2 allele were resist-
ant to AC220 treatment and their survival was significantly shortened
compared to controls (Fig. 2, G and H). Pim kinase expression thus
drives FLT3i resistance in MOLM-14 cells in vitro and in vivo.
Pim kinases, with a predominant implication of Pim-2,
regulate FLT3i-naïve and FLT3i-resistant AML cell survival
Pim-2 knockdown promoted apoptosis in two FLT3-ITD+ AML cell
lines (MOLM-14 and MV4-11; Fig. 3A). By contrast, it had no effect
on annexin V binding in FLT3 wild-type AML cell lines (THP-1, OCI-
AML3, and HL-60) or normal CD34+ hematopoietic progenitor cells
(Fig. 3, A and B). In contrast to other models (10) and to our observa-
tions in normal CD34+ hematopoietic progenitor cells, no compensa-
tory increase of other Pim kinase family members was seen after
Pim-1 or Pim-2 knockdown in AML cells (fig. S3A). In MOLM-14
cells, Pim-1 knockdown did not induce annexin V binding (fig. S3,
B and C) and reduced cell proliferation and viability, but to a lesser ex-
tent than did Pim-2 depletion (fig. S3D), suggesting the absence of func-
tional compensation between these kinases in AML. Decreased cell
viability induced by Pim-2 knockdown was rescued by ectopic murine
Pim-2 expression but not by a mutant Pim2 allele devoid of kinase ac-
tivity [kinase-dead Pim2 mutant (Pim2KD)] in MOLM-14 cells (Fig.
3C). These results suggest that Pim kinases, particularly Pim-2, are es-
sential to the survival of FLT3-ITD+ AML cells.Green et al. Sci. Adv. 2015;1:e1500221 18 September 2015We subcutaneously injected nude mice with MOLM-14 cells ex-
pressing in a Dox-inducible manner either a Pim-2 shRNA or a scram-
bled shRNA and followed leukemia propagation. Administration of
Dox impaired tumor growth in Pim-2 shRNA–expressing tumors rel-
ative to scrambled shRNA–expressing as well as vehicle-treated tumors
(Fig. 3, D and E). Corroborating these findings, Pim-2 knockdown
increased mouse survival (Fig. 3, F and G). Immunohistochemical anal-
ysis of tumor sections confirmed the efficiency and specificity of Pim-2
knockdown (Fig. 3H). Pim-2 knockdown also correlated with inhibi-
tion of 4E-BP1 phosphorylation, suggesting an efficient inhibition of
Pim-2–dependent signaling pathways in vivo (Fig. 3H) (16). Finally,
tumors with knockdown of Pim-2 exhibited increased cell death as
measured by TUNEL (terminal deoxynucleotidyl transferase–mediated
deoxyuridine triphosphate nick end labeling) staining (Fig. 3H).
We used AC220-treated MOLM-14 xenografts that became resist-
ant to therapy (Fig. 2E). Ex vivo cultures of these cells (referred to
as MOLM-14-R) devoid of FLT3 tyrosine kinase domain mutation
(FLT3-TKD; data not shown) confirmed our in vivo results (Fig. 2, E
and F), suggesting that these cells acquired AC220 resistance compared
to parental FLT3i-naïve MOLM-14 cells (Fig. 3I). Augmentation of
AC220 proapoptotic activity was observed in parental MOLM-14 cells
upon Pim-2 knockdown (Fig. 3I). Strikingly, Pim-2 knockdown induced
by Dox sensitized MOLM-14-R cells to AC220-induced apoptosis,
suggesting that AC220 resistance is associated with Pim-2 expression
in this model (Fig. 3I). Together, these data show that Pim-2 is in-
volved in FLT3i resistance in vitro and in vivo.
Pim kinase inhibition directly facilitates FLT3-ITD receptor
blockade by AC220
We measured intracellular calcium flow as a dynamic marker of FLT3-
dependent signaling pathway activation. Calcium mobilization was
promptly induced in Ba/F3-ITD cells—used as a minimal model of on-
cogene addiction to FLT3-ITD signaling (23)—after FLT3-L stimula-
tion, consistent with the sustained sensitivity of FLT3-ITD receptors to
FLT3-L in AML patients (Fig. 4A) (24). Ectopic expression of Pim2,
but not Pim2KD, allele abrogated FLT3-L–induced signaling, whereas
induction of calcium flux by thapsigargin was similar regardless of
transfectant (Fig. 4A). Co-incubation of Pim-2 and FLT3 recombinant
proteins decreased FLT3 tyrosine phosphorylation in vitro compared
to the level of FLT3 autophosphorylation (fig. S4A), and MOLM-14
cells transfected with Pim2 exhibited reduced FLT3 and STAT5 tyro-
sine phosphorylation, in contrast to Pim2KD transfectants (Fig. 4B).
These results suggest that Pim-2 activity inhibits FLT3-ITD signaling.
We used Ba/F3 cells transduced with FLT3-ITD alleles with wild-
type or D835Y mutated kinase domains. The FLT3-ITD-D835Y allele
modeled here conferred mutational resistance to FLT3i (6). We treated
both FLT3-ITD and FLT3-ITD-D835Y cells with the pan-Pim kinase
inhibitor LGB321 (25). FLT3-L stimulation increased calcium flux in
both FLT3-ITD and FLT3-ITD-D835Y cells treated with LGB321 com-
pared to vehicle-treated cells (Fig. 4C). In support of these results,
incubation of a mix of Pim-2 and FLT3 recombinant proteins with
LGB321 in vitro increased FLT3 tyrosine phosphorylation (fig. S4B).
These results suggest that Pim-2 directly controls FLT3 tyrosine phos-
phorylation and FLT3-ITD–dependent signaling pathway activation.
We co-incubated FLT3, Pim-2, and STAT5 recombinant proteins
in vitro without or with AC220 or LGB321 and then analyzed STAT5
tyrosine phosphorylation by immunoblotting using STAT5 as a direct
FLT3 substrate in vitro (26). Whereas LGB321 intrinsically had no5 of 13
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Fig. 3. Pim kinases, with a predominant implication of Pim-2, regulate FLT3i-naïve and FLT3i-resistant AML cell survival. (A) AML cell lines
(MOLM-14, MV4-11, HL-60, OCI-AML3, and THP-1) were transduced via lentivirus with a vector promoting the expression of an anti–Pim-2 shRNA after
induction with Dox (200 ng/ml). Apoptosis was quantified by annexin V staining after 4 days of shRNA induction (n = 3). The extent of Pim-2 knockdown
in each cell line was determined by Western blot (bottom). (B) Western blot for Pim-2 expression (top) and annexin V staining in normal CD34+ hemato-
poietic progenitor cells lentivirally transduced with scrambled (−) or Pim-2 (+) shRNA (n = 3). (C) Pim-2 shRNA–transduced MOLM-14 cells were
cotransfected with Pim2 or Pim2KD as indicated. Cell viability after Dox treatment was assessed by staining with the UptiBlue fluorescent reagent (n = 6).
(D to G) Tumor growth and survival (Kaplan-Meier curve) of MOLM-14 cells transfected with scrambled or Pim-2 shRNA and xenografted into nude mice.
Animals were treated with vehicle [phosphate-buffered saline (PBS), black line, n = 8] or Dox (200 mg/ml) (Pim-2 shRNA in red, scrambled shRNA in blue;
n = 8 for each). (H) Tumor sections stained by HES and TUNEL or labeled with Pim-1, Pim-2, and phospho-4E-BP1 (S65) antibodies. Representative
images from three separate experiments are shown. (I) MOLM-14 cells were harvested from AC220-treated xenografted mice as depicted in Fig. 2, E and F.
Pim-2 knockdown was induced with Dox (200 ng/ml) for 24 hours, and 2 nM AC220 was then added to the culture for an additional 24 hours. Apoptosis
was quantified by annexin V staining. Results are expressed as means ± SEM. b-Actin was used as a loading control for all Western blots. *P < 0.05,
**P < 0.01, ***P < 0.001, ****P < 0.0001.Green et al. Sci. Adv. 2015;1:e1500221 18 September 2015 6 of 13
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Fig. 4. Pim kinase inhibition directly facilitates FLT3-ITD receptor blockade by AC220. (A) Ba/F3 cells expressing FLT3-ITD, Pim2, and Pim2KD alleles
as single or combined transfectants as indicated were stained with Fluo-4 AM and treated or not with FLT3-L (30 ng/ml). Variations in intracellular calcium 6concentrations ([Ca2+]i) were evaluated. Fluorescence (485-nm excitation/516-nm emission) was acquired over time to evaluate the kinetics of response.
Variations are expressed as differences between the baseline and experimental [Ca2+]i elevations (DF/F0) (left), and [Ca
2+]i elevations (DF/F0) are expressed
as the mean area under the curves [change in relative fluorescence units (DRFU)] (right). Results are expressed as the mean of at least four independent
samples. Thapsigargin (10 mM) was used as a control for calciummobilization. (B) Protein extracts fromMOLM-14 cells expressing a control vector, Pim2, or
Pim2KD were assessed for FLT3 tyrosine phosphorylation (after FLT3 immunoprecipitation) as well as STAT5 (Y694) phosphorylation and Pim-2 and STAT5
expression by immunoblotting. (C) Parental Ba/F3 cells and Ba/F3 cells expressing FLT3-ITD or FLT3-ITD-D835Y alleles were treated with vehicle or 1 mM
LGB321 for 1 hour, and calcium flux was measured as detailed in (A). (D) STAT5, Pim-2, and FLT3 recombinant proteins were mixed together in a kinase
buffer without or with 1, 2, 5, 10, or 50 nM AC220 and without or with 1 mM LGB321 for 1 hour. Then, 200 mM ATP was added for 30 min, and proteins
were solubilized in Laemmli buffer and analyzed by immunoblotting with a phospho-STAT5 Y694 antibody. A representative Western blot is provided (top).
Signal intensity was quantified using MultiGauge software (Fujifilm), and results are presented with AC220 concentrations given in log scale and using the
log(inhibitor) versus response variable slope (four parameters) function of GraphPad v6 software. Results of IC50 for STAT5 phosphorylation without (−) or
with (+) LGB321 are provided (bottom) (n = 3). (E) Schematic representation of FLT3-ITD receptors and of Pim kinase consensus S935 site with either
nonphosphomimetic or phosphomimetic amino acid substitutions. (F and G) Ba/F3 cells were transduced with FLT3-ITD receptors either unmodified (ITD)
or harboring nonphosphomimetic (ITD-S935A) or phosphomimetic (ITD-S935D) amino acid substitutions. (F) Western blotting with phospho-FLT3 (Y591),
phospho-ERK (T202/Y204), phospho-STAT5 (Y694), FLT3, STAT5, and ERK antibodies. (G) Ba/F3 cells were cultured for 48 hours with vehicle or 5 nM AC220.
Apoptosis was measured by annexin V binding. Results are expressed as means ± SEM. b-Actin was used as a loading control for all Western blotting
experiments. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001.Green et al. Sci. Adv. 2015;1:e1500221 18 September 2015 7 of 13
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 impact on STAT5 phosphorylation (Fig. 4D and fig. S4C), addition of
this compound decreased the AC220 median inhibitory concentration
(IC50) for STAT5 phosphorylation (Fig. 4D), suggesting that Pim-2
inhibition facilitated AC220 competition with adenosine triphosphate
(ATP) for FLT3 receptors, facilitating AC220-induced FLT3 activity
blockade in vitro.
FLT3 harbors a consensus Pim phosphorylation motif (RKRPSF)
surrounding a serine residue at position 935 (S935), which is conserved
among species (fig. S4D). Phosphorylation of S935 by Pim-1 has re-
cently been reported to regulate FLT3 stability (27). We generated
both phosphomimetic (FLT3-ITD-S935D) and nonphosphomimetic
(FLT3-ITD-S935A) mutant alleles and expressed them in Ba/F3 cells (Fig.
4E). Compared to Ba/F3-ITD cells, Ba/F3 cells expressing the FLT3-ITD-
S935D phosphomimetic mutant had reduced FLT3 Y591 phosphoryl-
ation as well as decreased FLT3-dependent signaling as measured by
ERK (T202/Y204) and STAT5 (Y694) phosphorylation (Fig. 4F). In con-
trast, the FLT3-ITD-S935A nonphosphomimetic allele showed increased
Y591 phosphorylation along with enhanced ERK and STAT5 phospho-
rylation (Fig. 4F). Furthermore, introduction of the S935A mutation
augmented the proapoptotic effects of AC220, whereas the S935Dmu-
tation abrogated AC220-induced annexin V binding (Fig. 4G). Togeth-
er, these results suggest that a FLT3-ITD consensus site for Pim kinase
phosphorylation regulates FLT3-dependent signaling and that abroga-
tion of S935 phosphorylation restores FLT3-ITD sensitivity to FLT3i.
Combined inhibition of Pim and FLT3 eradicates
FLT3-mutated cells
The F691L and D835Y FLT3 kinase domain mutants (Fig. 5A) are
frequently correlated to FLT3i resistance in AML patients (6). FLT3-
ITD alleles harboring these mutations were expressed in Ba/F3 cells
via lentivirus. Relative to Ba/F3-ITD cells, expression of these mutants
conferred resistance to AC220-induced cytotoxicity but had no impact
on sensitivity to LGB321 (fig. S2, A and B). Coadministration of LGB321
sensitized FLT3-ITD as well as FLT3-ITD-F691L and FLT3-ITD-
D835Y cells to AC220, as measured by the reduction of IC50 for AC220
cytotoxicity (Fig. 5B and fig. S5C).
AC220 monotherapy induced annexin V binding in Ba/F3-ITD and
moderately in Ba/F3-ITD-D835Y, but not in Ba/F3-ITD-F691L cells
(fig. S5D). LGB321 enhanced the proapoptotic effect of AC220 in FLT3-
ITD and FLT3-ITD-D835Y cells and triggered apoptosis in FLT3-ITD-
F691L cells (fig. S5D). In FLT3-ITD-D835Y cells, the combination of
LGB321 and AC220—but not AC220 monotherapy—inhibited ERK
and STAT5 phosphorylation (Fig. 5C). In FLT3-ITD cells, coadminis-
tration of LGB321 amplified AC220-induced inhibition of STAT5 and
ERK phosphorylation (fig. S5E). Similar results were obtained with the
dual Pim/FLT3 inhibitor SGI-1776 (fig. S5F) (28). These results indi-
cate that LGB321 restores sensitivity to AC220 in FLT3-ITD cells with
kinase domain mutation–induced resistance to FLT3i.
We compared the effects of four clinically used FLT3i agents in Ba/
F3 cells expressing FLT3-ITD (Ba/F3-ITD, sensitive to FLT3i) or FLT3-
ITD with the F691L mutation (Ba/F3-F691L, resistant to most FLT3i)
(29). All four FLT3i agents induced annexin V binding, and cotreatment
with LGB321 significantly enhanced their efficacy in Ba/F3 FLT3-ITD
(Fig. 5D). In contrast, F691L cells were resistant to type II tyrosine ki-
nase inhibitors (TKIs) (AC220 and sorafenib) and were only sensitive
to high doses of type I TKIs (PKC412 and crenolanib) (Fig. 5D) (2, 30).
Strikingly, cotreatment with LGB321 sensitized these cells to both type
I and type II TKIs (Fig. 5D).Green et al. Sci. Adv. 2015;1:e1500221 18 September 2015We expressed FLT3-ITD or FLT3-ITD-D835Y alleles in MOLM-14
cells, and Pim-2 expression was still observed despite FLT3 inhibition
by AC220 (Fig. 5E). Whereas MOLM-14-ITD cells were sensitive to
AC220, expression of the D835Y allele blunted AC220-induced apoptosis
(Fig. 5F), suggesting that this transgene exerts dominant effects on the
endogenous FLT3-ITD receptor. In MOLM-14-D835Y cells, coadmin-
istration of LGB321 enhanced AC220-induced apoptosis (Fig. 5F). AC220
induced annexin V binding in FLT3-ITD+ cell lines (MOLM-14 and
MV4-11) and LGB321 enhanced this effect, contrary to the observa-
tions in FLT3 wild-type cells (OCI-AML2, OCI-AML3, and THP-1)
(Fig. 5G). AC220 and LGB321 demonstrated synergistic activity in those
cell lines (fig. S5G). In primary FLT3-ITD+ AML samples (table S1),
AC220 monotherapy induced minimal apoptosis in vitro, which is a
frequent finding even in the absence of previous exposure to FLT3i
(31, 32), but coadministration with LGB321 significantly induced an-
nexin V binding (n = 7; Fig. 5H). On the other hand, these agents had
no impact on annexin V binding in FLT3 wild-type primary AML
samples (n = 3; Fig. 5H). These results suggest that Pim kinase inhi-
bition enhances the efficacy of FLT3i in the context of various FLT3
mutations.DISCUSSION
FLT3-ITD is a frequent genetic event in AML and confers a poor
prognosis due to an increased relapse rate despite intensive chemo-
therapy (33). In phase 1/2 clinical trials, ATP-competitive FLT3i have
shown promising results with acceptable toxicity (4, 34). However, re-
sponses are transient, and FLT3i resistance is virtually inevitable (34).
The rapid emergence of TKD-mutated subclones in a subset of FLT3i-
treated patients pinpointed FLT3 signaling as a critical molecular event
for disease propagation (6). However, most relapsing patients do not
manifest new FLT3 mutations, suggesting the existence of alternative
pathways involved in FLT3i resistance (9). Compensatory activation
of alternative signaling pathways (18, 21, 35), leukemia-permissive in-
teractions with the bone marrow microenvironment (20, 36), and hy-
peractivation of spleen tyrosine kinase (SYK) (37) have been proposed
as explanatory models.
We and others have previously reported an important role for Pim
kinases in AML biology (16, 38, 39) and suggested that combining FLT3
and Pim kinase inhibitors may be relevant in FLT3-ITD+ AML (40, 41).
Here, we built on these studies by showing that Pim kinases (particu-
larly Pim-2) are overexpressed in FLT3-ITD+ AML patients refractory
to FLT3i, regardless of their FLT3-TKDmutational status. Whereas FLT3-
ITD+ cells are addicted to both Pim-1 and Pim-2 expression, the impact
of Pim-2 on AML cell survival appears higher without significant
functional compensation between these kinases. In addition, a STAT5-
independent regulation of Pim-2 downstream of FLT3-ITD receptors—
in contrast to Pim-1 in our model—led us to consider these kinases
separately and to focus on Pim-2 in AML. In murine FLT3-ITD–induced
MPN and AML models, ectopic Pim-2 expression decreases FLT3i ef-
ficacy, and in AML xenografts resistant to AC220, Pim-2 knockdown
restores FLT3i sensitivity. Augmented Pim kinase activity thus drives
FLT3i resistance in FLT3-ITD+ AML.
Previous studies in minimal cellular models suggest that Pim ki-
nase overexpression reduces the efficacy of FLT3i (11, 17). However,
the molecular mechanisms, cellular consequences, and clinical
application of this observation have yet to be fully characterized.8 of 13
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Fig. 5. Combined inhibition of Pim and FLT3 eradicates FLT3-mutated cells. (A) Schematic representation of FLT3i resistance-conferring mutations
within the FLT3-ITD kinase domain. (B) Cell viability measured by a CellTiter-Glo assay in FLT3-ITD-D835Y–transduced Ba/F3 cells treated with log dilutions
of AC220 without or with 3.2 nM LGB321. Relative luminescence (RLU) was normalized to vehicle-treated cells for each condition (normalized RLU). Results
are presented using the log(inhibitor) versus response variable slope (four parameters) function of GraphPad v6 software. The IC50 values for this assay are
provided (bottom) (n = 3). (C) Ba/F3 ITD-D835Y cells were cultured without or with 5 nM AC220 and/or 1 mM LGB321 for 4 hours. Western blots were done
with phospho-STAT5 (Y694), phospho-ERK (T202/Y204), phospho-P70S6K (T389), STAT5, ERK, and P70S6K antibodies. (D) Ba/F3 cells expressing FLT3-ITD or
FLT3-ITD-F691L alleles were cultured for 48 hours with 1 mM LGB321 and increasing doses of TKIs (AC220, sorafenib, PKC412, and crenolanib), as indicated.
Apoptosis was determined by annexin V staining (n = 3 for each). (E and F) Ectopic expression of FLT3-ITD or FLT3-ITD-D835Y alleles with a lentiviral vector
in MOLM-14 cells. (E) Western blotting with a Pim-2 antibody, using protein extracts from MOLM-14-ITD or MOLM-14-ITD-D835Y cells treated with vehicle
or 5 nM AC220 for 24 hours. (F) Cells were treated with vehicle, 1 mM LGB321, 5 nM AC220, or the combination of LGB321 and AC220 for 48 hours, and
apoptosis was quantified by annexin V staining. (G and H) AML cell lines (MOLM-14, MV4-11, OCI-AML2, OCI-AML3, and THP-1) (G) and primary FLT3-ITD+
(n = 7) or FLT3-WT (n = 3) AML samples (H) were cultured with vehicle, 1 mM LGB321, 5 nM AC220, or the combination of LGB321 and AC220 for 48 hours,
and annexin V staining was measured. (I) Explanatory model. Baseline: FLT3-ITD receptors (ITD) constitutively activate prosurvival signaling pathways
including Pim-1 (through STAT5 activation) and Pim-2 (through an unknown STAT5-independent mechanism). FLT3i inhibit FLT3 activity and induce
cytotoxicity. FLT3i resistance: Increased Pim kinase expression is found in FLT3i-resistant AML cells. Pim kinases have intrinsic oncogenic properties in
favor of AML cell survival. They also induce direct FLT3-ITD receptor modifications (including S935 phosphorylation) contributing to FLT3i resistance. Pim/FLT3
inhibition: Genetic or pharmacological Pim kinase inhibition restores FLT3i activity against FLT3-ITD receptors, leading to synergistic cytotoxicity. b-Actin was
used as a loading control for all Western blotting experiments. Results are expressed as means ± SEM. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001.Green et al. Sci. Adv. 2015;1:e1500221 18 September 2015 9 of 13
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 Pim kinases exert oncogenic effects by modulating multiple targets
involved in cellular proliferation and apoptosis (10). Accordingly,
Pim kinase inhibition reduces AML cell viability and Pim-2
knockdown blocks disease propagation in FLT3-ITD+ AML xeno-
grafts. Addiction to Pim kinases may thus intrinsically contribute
to FLT3i resistance. In addition, we unexpectedly found that Pim
kinases directly modulate FLT3-ITD receptor activity and response
to ATP-competitive inhibitors.
The regulation of FLT3-ITD by tyrosine phosphorylation is well
established (42). Puissant and colleagues (37) reported that FLT3 tyro-
sine phosphorylation by SYK is critical for both FLT3-ITD–induced
transformation and FLT3i resistance. In contrast, the role of FLT3 ser-
ine phosphorylation has only recently emerged. Natarajan and collea-
gues (27) showed that Pim kinases directly phosphorylate and stabilize
FLT3 in vitro. Although in our model the impact of Pim kinase–induced
FLT3 glycosylation on resistance to FLT3i seems limited, we suggest
that the consensus Pim kinase residue S935 is involved in the affinity of
FLT3-ITD receptors for FLT3i because a nonphosphomimetic mutant
(S935A)—which mimics the impact of Pim kinase inhibition on this
residue—augments AC220-induced cytotoxicity. These results provide
an explanatory model to understand the synergy between FLT3 and
Pim kinase targeting in AML (Fig. 5I).
We further hypothesize that FLT3i resistance mediated by Pim ki-
nases may involve steric modification of the FLT3 kinase domain.
Sensitivity to FLT3i was elicited by Pim kinase inhibition across mul-
tiple FLT3-ITD kinase domain–mutant cell lines, including those ex-
pressing the FLT3-F691L allele. The F691L amino acid substitution
involves a kinase domain “gatekeeper” position, similar to the T315I
substitution in ABL1 kinase, which confers broad-spectrum resistance
to TKIs in BCR-ABL malignancies (29). In F691L-mutated cells, re-
sistance to FLT3i is abrogated by Pim kinase inhibition—regardless of
the use of type I or type II FLT3i—supporting our model of steric FLT3
kinase domain changes induced by Pim kinases. Because FLT3-ITD
subcellular localization regulates its activity (43), we hypothesize that
Pim kinases may have an impact on FLT3-ITD trafficking with poten-
tial implications in receptor conformation and affinity for FLT3i, and
this point should be investigated for each FLT3-ITD kinase domain
mutant allele in future studies.
Drug resistance invariably occurs in FLT3i-treated AML patients,
underscoring the importance of understanding the landscape of resist-
ance mechanisms to FLT3i as we design therapeutic modalities that
are more effective for this disease (9). Our results suggest that deregu-
lation of Pim kinase activity is a recurrent resistance mechanism to
FLT3i and that dual inhibition of Pim and FLT3 kinase efficiently
targets FLT3-ITD+ malignancies, as shown in primary samples from
AML patients. Whereas the pharmacological profile of Pim and FLT3
dual targeting may appear favorable, taking into account that multidrug
resistance effectors such as the ABCG2 drug transporter are directly
activated by Pim kinases (44), careful pharmacokinetic studies should be
conducted before administration in AML patients. Ideally, dual-activity
molecules rather than combination therapies should be developed in this
setting, even if the first-in-class dual Pim/FLT3 inhibitor SGI-1776
was withdrawn from clinical development because of unanticipated
cardiac toxicity (45). Given the recent development of new FLT3i-
targeting TKD mutant receptors such as crenolanib (29, 32, 46), the
design of highly active and safe dual Pim/FLT3 inhibitors represents a
fascinating challenge to make possible new therapeutic strategies in
this particularly aggressive subtype of AML.Green et al. Sci. Adv. 2015;1:e1500221 18 September 2015METHODS
Primary cells
Patients with FLT3-ITD+ AML who had relapsed or had been refrac-
tory after two courses of standard chemotherapy or who were con-
sidered unfit for conventional treatment were recruited into a phase
2 clinical trial of sorafenib monotherapy as approved by the local in-
stitutional review board (IRB) of Hong Kong West Cluster/The
University of Hong Kong (IRB UW 10-393). Briefly, patients were
treated with a continuous course of sorafenib at 200 to 400 mg twice
daily until allogeneic bone marrow transplantation or leukemia pro-
gression. Bone marrow or peripheral blood samples were obtained
before sorafenib treatment (naïve) or during subsequent progression
(resistant). We also collected blast cells from the bone marrow or
blood of FLT3-ITD+ AML patients treated in Cochin Hospital after
obtaining approval from the hospital’s ethics committee. Normal
CD34+ hematopoietic cells were obtained from healthy donors.
Informed consent was obtained from each patient and healthy donor
in accordance with the Declaration of Helsinki.
Cell lines and reagents
The MOLM-14, MV4-11, OCI-AML2, OCI-AML3, THP-1, and HL-60
human AML cell lines were cultured in a-modified Eagle’s medium
(aMEM) supplemented with 10% fetal calf serum (FCS) (47). We eval-
uated these cell lines for FLT3-ITD, FLT3-TKD, NPM1, n-ras, IDH1,
IDH2, DNMT3A, and TP53 gene mutations (table S2). Ba/F3 cells
transfected or not with ITD-mutated FLT3 with or without a TKDmu-
tation (F691L, D835Y, S935A, or S935D) were grown in RPMI with
10% FCS, supplemented with 10% WEHI-3–conditioned medium
as a source of interleukin-3 (IL-3) in the case of parental Ba/F3 cells (48).
Dox (Sigma-Aldrich) was used in vitro at a concentration of 200 ng/ml
in cell culture experiments (49–51) and at 200 mg/ml in mouse experi-
ments. The endoplasmic reticulum calcium ATPase inhibitor thapsigargin
(Sigma-Aldrich) was used at 10 mM as a control for calcium mobiliza-
tion. We also used AC220, PKC412, sorafenib, and crenolanib (all from
Selleck Chemical) at various concentrations as indicated. AC220 was
also used at 1 mg/kg in mouse experiments. Murine IL-3 and FLT3-L
were purchased from PeproTech. The pan-Pim kinase inhibitor LGB321
was fromNovartis Pharmaceutical (25). The construction of mammalian
expression plasmids for PIM1, PIM2, Pim2, Pim2 kinase domain K61A
mutant (kinase-dead or KD), and various FLT3-ITD mutants is de-
scribed in the Supplementary Materials.
Western blotting
Whole-cell protein extraction andWestern blotting were performed as
previously described (16, 41, 52). The antibodies used in this study are
described in table S2.
Retroviral infection of bone marrow cells and transplantation
Bone marrow cells were harvested from the femurs and tibias of fe-
male C57BL/6 mice, immediately infected with FLT3-ITD–containing
retroviruses, and cultured in Iscove’s modified Dulbecco’s medium
(IMDM) supplemented with 10% FCS, IL-3 (10 ng/ml), IL-6 (10 ng/ml),
and stem cell factor (100 ng/ml). Cells were transduced with PIM2 or
control lentiviruses and cultured for 5 days under puromycin selec-
tion. Transduced bone marrow cells (2 × 105) were transplanted via
retroorbital intravenous injection into sublethally irradiated recipient
mice (250 cGy, n = 4 for each group). Body weights were monitored10 of 13
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 weekly. Peripheral blood was collected at 4, 8, and 12 weeks after trans-
plantation in EDTA-coated tubes, and complete blood counts were mea-
sured on an MS9-5 Blood Analyzer (Melet Schloesing Laboratoires).
After sacrifice, spleens were measured, weighed, and either fixed in 4%
formalin or subjected to cell dispersion by passaging through a 70-mm
cell strainer in PBS containing 1% bovine serum albumin. Cells were
electronically counted with a Scepter automated cell counter (Millipore).
RNA interference
The Tet-pLKO-puro plasmid (49) (Addgene plasmid 21915) was used
to express hairpins targeting Pim-2 or FLT3 in a Dox-dependent manner
after lentiviral delivery. The sequences were 5′-GATGAACCCTACACT-
GACTTT-3′ (Pim-2) and 5′-GCATCCCAGTCAATCAGCTTT-3′
(FLT3). Scrambled and Pim-2 hairpins expressed in a noninducible
pLKO vector were purchased from Thermo Scientific.
Flow cytometry
Apoptosis was measured by annexin V–phycoerythrin (Becton Dickinson)
staining according to the manufacturer’s instructions.
AML xenografts in nude mice
MOLM-14 cells stably expressing the shPim-2 pLKO-Tet-On vector
were subcutaneously injected into nude mice. Detailed procedures for
follow-up of tumor growth, survival, immunohistochemistry, and TUNEL
assays are provided in the Supplementary Materials. All experiments
were conducted in accordance with the guidelines of the Association
for Assessment and Accreditation of Laboratory Animal Care Interna-
tional and after approval of the local ethics committee.
Cell viability assays
UptiBlue. AML cells were plated in triplicate at 2.5 × 104 in 100 ml
of 5% FCS–supplemented MEM for 48 hours. The UptiBlue viable cell
counting reagent (Interchim) was then added for 3 hours according to
the manufacturer’s instructions, and fluorescence was measured with a
Typhoon 8600 scanner (GE Healthcare Bio-Sciences).
CellTiter-Glo. Cells were plated at a concentration of 4 × 104/ml
in 50 ml of 10% FCS–supplemented MEM (2 × 103 cells per well) and
cultured in the presence of drugs for 48 hours at 37°C. Viability was
quantified by the luminescence-based CellTiter-Glo assay (Promega)
following the manufacturer’s instructions. Luminescence was measured
with the EnVision plate reader (Perkin Elmer). Luminescence values
were normalized to dimethyl sulfoxide–treated controls for each cell line.
IC50 values were calculated with GraphPad Prism v6 (GraphPad) (53).
Measurement of free intracellular calcium
Ba/F3 or Ba/F3 FLT3-ITD cells were transduced with control, Pim2
(murine Pim-2), or Pim2KD lentiviruses. Free intracellular calcium
content was measured using the Fluo-4 Direct Calcium Assay Kit
(Invitrogen) as indicated by the manufacturer. Changes in cytosolic
free calcium were quantified as RFU using a microplate reader (Tecan
Infinite M200 and Magellan software, Tecan). Detailed procedures are
provided in the Supplementary Materials.
In vitro kinase assays
STAT5 (reference no. SRP5142), Pim-2 (reference no. K3518), and
FLT3 571-993 (reference no. F6432) recombinant proteins were from
Sigma-Aldrich and were used at a concentration of 200 ng in a final
volume of 100 ml. Proteins were mixed in a kinase reaction buffer (CellGreen et al. Sci. Adv. 2015;1:e1500221 18 September 2015Signaling Technology, reference no. 9802) with 0, 1, 2, 5, 10, or 50 nM
AC220 and 0 or 1 mM LGB321 and incubated for 1 hour at 37°C.
Then, 200 mM ATP (Cell Signaling Technology, reference no. 9804)
was added, and the mixture was further incubated for 30 min at 37°C.
The reactions were stopped by the addition of boiling Laemmli buffer.
Statistics
Differences between the mean values obtained for the experimental groups
were analyzed using two-tailed Student’s t test. Statistical analyses were
performed using Prism software (GraphPad).SUPPLEMENTARY MATERIALS
Supplementary material for this article is available at http://advances.sciencemag.org/cgi/
content/full/1/8/e1500221/DC1
Fig. S1. Pim kinase expression in AML.
Fig. S2. Pim-2 regulation by downstream FLT3-ITD receptors.
Fig. S3. Pim-1 and Pim-2 regulation by FLT3-ITD receptors.
Fig. S4. Direct phosphorylation of FLT3 receptors by Pim-2.
Fig. S5. Dual inhibition of FLT3 and Pim kinases produces synergistic cytotoxicity in AML.
Table S1. Genotyping of AML cell lines used in the current study.
Table S2. References of the antibodies used in the current study.
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